Trial Profile

A randomized, single-blind, placebo-controlled, 4-way crossover phase I pharmacokinetic (PK) study of ORMD-0901

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exenatide (Primary) ; Exenatide
Indications Type 2 diabetes mellitus
Focus Adverse reactions; Pharmacokinetics
Sponsors Oramed Pharmaceuticals

Most Recent Events

27 Feb 2020 According to an Oramed Pharmaceuticals media release, the company announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $4.00 per share and the company intends to use the net proceeds of the offering for this trial.
18 Jun 2019 Status changed from recruiting to completed, according to an Oramed Pharmaceuticals media release.
15 Jan 2019 Status changed from planning to recruiting, according to an Oramed Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com